cancer-recurrence
(2)
The Urine Test That Reads Cancer's Mail Twelve Years Early
No scope, no needle - just a cup of urine and 60 genes worth of warning. Convergent Genomics is betting that bladder cancer leaves a paper trail years before a doctor can see it.
SURGE Therapeutics
SURGE Therapeutics is a Cambridge, Massachusetts clinical-stage biotech building intraoperative immunotherapy: a biodegradable, injectable hydrogel (SURGERx) placed directly into the surgical wound at the moment a tumor is removed. The goal is to turn the body's post-surgical inflammation from immunosuppressive to immunostimulatory and stop residual cancer cells from seeding recurrence and metastasis. Founded on research from Harvard Medical School and led by founder-CEO Michael Goldberg, Ph.D., the company has raised about $58M and is advancing its lead candidate SRG-514 toward a registrational trial in triple-negative breast cancer.